Knight Therapeutics signs a new distribution agreement with Gilead Sciences


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Knight Therapeutics signs a new distribution agreement with Gilead Sciences
The agreement will enter into force as of 1st January 2021

Knight Therapeutics Inc., a leading Pan American (ex. EU) specialty pharmaceutical company, announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. for the marketing of AmBisome (liposomal amphotericin B) in Brazil. The agreement will enter into force as of 1st January 2021.

“We are pleased to continue this already established partnership and are very grateful to Gilead for the continued trust in the Knight team,” said Samira Sakhia, President and COO of Knight. Our Brazilian team launched AmBisome in Brazil over 20 years ago and we are excited to continue the great work we have done with patients and physicians ”.

"The signing of this new agreement extends the historic collaboration between Gilead and Grupo Biotoscana (" GBT ") and confirms Knight's assessment of the GBT acquisition," said Amal Khouri, vice president of business development at Knight.

“Gilead values ​​the ongoing partnership with GBT to meet medical needs in Brazil,” said Ahmed Afifi, vice president and head of the Latin America region at Gilead Sciences. With this new agreement, we are pleased to continue our cooperation with the extended GBT / Knight team to enable Brazilian patients to benefit from AmBisome ”.

AmBisome (Liposomal Amphotericin B) is a sterile lyophilized, non-pyrogenic intravenous infusion of liposomal amphotericin B. This medicinal product is indicated for the treatment of serious deep mycotic infections and / or endemic and opportunistic systemic mycoses, for the treatment of fever of undetermined origin (FOI) in neutropenic patients for whom the FOI corresponds persistent fever, which does not respond to antibiotic therapy after 96 hours and which is very indicative of a systemic fungal infection, as the primary therapy for visceral leishmaniasis in immunocompetent patients. AmBisome is a registered trademark of Gilead Sciences, Inc. and is the subject of a license from Gilead and has been in the portfolio of Knight's Brazilian subsidiary for over twenty years. Knight's subsidiaries are responsible for the distribution and commercial activities of AmBisome in Brazil as well as Bolivia, Paraguay and Peru.

Tags : #KnightTherapeutics #LatestNewsonKnightTherapeutics27thOct #GileadSciences #LatestNewsonGilead #Sciences27thOct #LatestPharmaNews27thOct #LatestPharmaCollaboration27thOct #BrainCancer #Brazil #AhmedAfifi #AmalKhouri

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026